Quadrupling Inhaled Glucocorticoid Dose to Abort Asthma Exacerbations

Area of Science:

• Pulmonology
• Clinical Medicine
• Pharmacology

Background:

• Asthma exacerbations pose significant risks, including fatality.
• Current management often relies on reactive strategies.
• A proactive approach using personalized self-management plans is being investigated.

Purpose of the Study:

• To evaluate the efficacy of a self-management plan incorporating a temporary dose increase of inhaled glucocorticoids for managing asthma control.
• To determine if this strategy reduces the incidence of severe asthma exacerbations in adults and adolescents.

Main Methods:

• A pragmatic, unblinded, randomized trial was conducted over 12 months.
• Participants received inhaled glucocorticoids and were randomized to a self-management plan with (quadrupling group) or without (non-quadrupling group) a fourfold temporary increase in inhaled glucocorticoid dose.
• Severe asthma exacerbation was defined as systemic glucocorticoid treatment or unscheduled healthcare consultation.

Main Results:

• A total of 1922 participants were randomized, with 1871 in the primary analysis.
• The quadrupling group experienced fewer severe exacerbations (45%) compared to the non-quadrupling group (52%), with an adjusted hazard ratio of 0.81 (P=0.002).
• Adverse effects, mainly local, were more frequent in the quadrupling group.

Conclusions:

• A personalized asthma self-management plan with a temporary quadrupling of inhaled glucocorticoid dosage effectively reduces severe asthma exacerbations.
• This strategy provides a proactive method for improving asthma control in adults and adolescents.
• While effective, potential increases in local side effects should be considered.